U.S. markets open in 1 hour 6 minutes

  • S&P Futures

    4,563.00
    -2.25 (-0.05%)
     

  • Dow Futures

    35,662.00
    +18.00 (+0.05%)
     

  • Nasdaq Futures

    15,533.00
    -12.00 (-0.08%)
     

  • Russell 2000 Futures

    2,283.30
    -10.60 (-0.46%)
     

  • Crude Oil

    83.77
    -0.88 (-1.04%)
     

  • Gold

    1,797.20
    +3.80 (+0.21%)
     

  • Silver

    24.17
    +0.08 (+0.34%)
     

  • EUR/USD

    1.1623
    +0.0020 (+0.17%)
     

  • 10-Yr Bond

    1.6190
    0.0000 (0.00%)
     

  • Vix

    16.13
    +0.89 (+5.84%)
     

  • GBP/USD

    1.3747
    -0.0016 (-0.12%)
     

  • USD/JPY

    113.6840
    -0.4450 (-0.39%)
     

  • BTC-USD

    58,927.45
    -3,715.43 (-5.93%)
     

  • CMC Crypto 200

    1,415.40
    -89.75 (-5.96%)
     

  • FTSE 100

    7,271.38
    -6.24 (-0.09%)
     

  • Nikkei 225

    29,098.24
    -7.77 (-0.03%)
     

The Worldwide Radiotherapy, Radiopharmaceuticals and Nuclear Medicine Industry is Expected to Reach $28.5 Billion by 2026

·7 min read

DUBLIN, Oct. 27, 2021 /PRNewswire/ -- The "Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

This report examines the current and forecasted market potential of radiopharmaceuticals and therapeutics. It offers a detailed analysis of the technological advancement, competitive environment, market background, drivers and restraints, and market growth trends.

The research report also includes market projections to 2026. The scope of this report is broad and covers type, production method, technology and applications of radiopharmaceuticals and therapeutics. By type, the market has been segmented into radiotherapy and radiopharmaceuticals. Revenue forecasts from 2021 to 2026 are provided for each segment and regional market, with estimated values derived from manufacturers' total revenues.

The global radiopharmaceuticals and therapeutics market should reach $28.5 billion by 2026 from $18.2 billion in 2021 at a compound annual growth rate (CAGR) of 9.4% for the forecast period of 2021 to 2026.

The North American radiopharmaceuticals and therapeutics market is expected to grow from $7.0 billion in 2021 to $11.1 billion in 2026 at a CAGR of 9.5% for the forecast period of 2021 to 2026.

The Asia-Pacific radiopharmaceuticals and therapeutics market is expected to grow from $4.5 billion in 2021 to $7.2 billion in 2026 at a CAGR of 10.0% for the forecast period of 2021 to 2026.

The report additionally includes a discussion of the major market players in radiopharmaceuticals and therapeutics. Further, it explains the major drivers and regional dynamics of the global radiopharmaceutical and therapeutics market and current trends within the industry.

By geography, the radiopharmaceutical and therapeutics market has been segmented into Europe, North America, Asia-Pacific (APAC) and the Rest of the World (RoW).

The detailed analyses of major countries such as the U.S., Germany, Canada, the U.K., Spain, France, Japan, India and China are covered in regional segments. For market estimates, data is provided for 2020 as the base year, 2021 and forecast through year-end 2026. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

  • 52 data tables and 72 additional tables

  • An overview of the global market for radiotherapy, radiopharmaceuticals, and nuclear medicines

  • Estimation of the market size and analyses of the global market trends, with data from 2019 to 2020, estimates for 2021, with projection of CAGR through 2026

  • Analysis of new opportunities, challenges, and technological changes within the industry and highlights of the market potential by type, method, technology, application and region

  • Assessment of present and future strategies within the radiopharmaceuticals market, including radiopharmaceuticals for both diagnostic and therapeutic purposes

  • Description of positron emission tomography (PET) and single photon emission computed tomography (SPECT) and discussion of their applications

  • Evaluation of market opportunities for external beam radiation therapy, internal radiation therapy and systemic radiotherapy

  • Detailed analysis of the current market trends and forecast, relevant R&D activities, new products launches and product enhancement in the industry and discussion of regulatory elements that are affecting the future marketplace

  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies

  • Company profiles of major players in the market, including Accuray Inc., Bayer Pharma AG, Cardinal Health, General Electric Co., Nordion Inc. and Siemens Healthineers AG

Population and human life expectancy are increasing globally, spurring more chronic conditions and life-threatening diseases. A sedentary lifestyle, obesity and a lack of physical activity have further worsened the situation, leading to the increased importance of medical treatments and interventions.

Despite incredible improvements in the field of medicine in the last few decades, an unmet need remains for the diagnosis, prevention, and treatment of aggressive ailments such as cardiovascular diseases, central nervous system disorders and cancer.

Since the discovery of radioactivity, it has been observed that radiation can play a role in the treatment of several diseases. Radiopharmaceuticals are a type of radioactive drug internally administered and intended to diagnose and treat diseases. Radiopharmaceuticals are now a vital part of the healthcare industry, as they can identify several disease processes much earlier than other diagnostic tests.

Applications of radiopharmaceuticals are rising significantly in the fields of neurology, oncology, cardiology and other medical specialties, such as gastroenterology, endocrinology and nephrology, for therapeutic and diagnostic purposes. Radiopharmaceuticals have also become a necessary part of personalized medicine. The market for therapeutic radiopharmaceuticals is anticipated to grow at a steep rate in the coming years due to growing applications and increased demand.

Growing acceptance and utilization of nuclear medicine scans (i.e., PET and SPECT) and better availability of radiopharmaceuticals due to a growing number of cyclotrons have significantly further contributed to growth in the radiopharmaceutical industry.

Innovative technological devices leading to early and accurate diagnoses, increased awareness of radiopharmaceuticals among patients and physicians and new regulatory approvals of radiopharmaceuticals are other major driving forces for the global radiopharmaceutical market. Furthermore, rising incidences of different types of cancers across the globe are considered a significant driver behind the growth of radiopharmaceuticals and therapeutics.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Regulatory Scenario

  • Regulatory Outlook

  • United States

  • Canada

  • Australia

  • India

  • European Union

Chapter 4 Radiopharmaceuticals and Therapeutics: Background

  • Introduction

  • Uses of Radiopharmaceuticals

  • Evolution and Transition of Radiopharmaceuticals

  • Radiotherapy

  • Ionizing Radiation

  • Non-ionizing Radiation

  • Evolution and Transition of Radiation Therapy

  • The Discovery Period: 1890s

  • Kilovoltage Era: 1900-1940

  • Megavoltage Era: 1946-1996

  • Computer-Assisted Era: 1996-Present

  • Market Potential

  • Investment Analysis

  • Radiotherapy Subsegments

  • Radiotherapy Subsegments by Type

  • Radiopharmaceuticals Subsegments by Type

  • Production Method Subsegments

  • Technology Subsegments

  • Radiopharmaceuticals and Therapeutics, by Application

Chapter 5 Market Dynamics

  • Trends

  • Respiratory Gating

  • Proton Therapy

  • Carbon Ions

  • Magnetic Resonance-Driven Linear Accelerator

  • Drivers

  • Increasing Aging Population

  • Increasing Incidence of Life-Threatening Diseases

  • Increasing Incidence of Cancer

  • High Incidence of Cancer in Aging Population

  • Growing Healthcare Spending in Emerging Regions

  • Advancements in Technology

  • Growing Focus on Early Diagnosis and Treatment

  • Increasing Number of Cyclotrons

  • Increasing Amount of Nuclear Imaging Equipment

  • High Efficiency of Radiotherapy

  • Palliative Radiation Therapy

  • Restraints and Challenges

  • Limited Global Supply of Medical Isotopes

  • Reimbursement Policies

  • Regulatory Issues

  • Expensive Equipment

  • Lack of Trained Professionals

  • Limited Effectiveness against Metastatic Cancer

  • Side Effects of Radiation Therapy

  • Opportunities

  • Developing Countries

  • Replacement of Old Equipment

Chapter 6 Impact of COVID-19 Pandemic

  • Introduction

  • Impact of COVID-19 on Radiopharmaceuticals and Therapeutics

  • Impact on Cancer Research

  • Public Health Impact of COVID-19 Across the Cancer Continuum

Chapter 7 Market Breakdown by Type

  • Radiotherapy

  • External Beam Radiation Therapy

  • Internal Radiation Therapy

  • Systemic Radiotherapy

  • Radiopharmaceuticals

  • Diagnostics

  • Therapeutics

Chapter 8 Market Breakdown by Production Method

  • Particle Accelerators (Cyclotrons)

  • Particle Accelerator Process

  • Nuclear Reactors

  • Radionuclide Generators

  • Production of Radioisotopes Through Radionuclides

Chapter 9 Market Breakdown by Technology

  • External Radiotherapy by Technology

  • Particle Therapy/Proton Beam Therapy

  • Stereotactic Radiosurgery (SRS) and Fractionated Stereotactic Radiation Therapy

  • Image-Guided Radiation Therapy (IGRT)

  • Intensity-Modulated Radiation Therapy (IMRT)

  • Tomotherapy

  • Three-Dimensional Conformal Radiation Therapy (3D-CRT)

  • Volumetric Modulated Arc Therapy (VMAT)

  • Internal Radiotherapy by Technology

  • Pulsed-Dose-Rate (PDR) Brachytherapy

  • Low-Dose-Rate Brachytherapy

  • High-Dose-Rate (HDR) Brachytherapy

  • Systemic Radiotherapy by Technology

  • Comparison between Alpha and Beta Emitters

Chapter 10 Market Breakdown by Application

  • External Beam Radiation Therapy

  • Treatment Planning for External Beam Radiation

  • Dosing and Treatment with External Beam Radiation

  • Electron-Emitting High-Energy Linear Accelerators (LINACs)

  • Internal Radiation Therapy

  • Applications of Internal Beam Radiation Therapy

  • Systemic Radiation Therapy

  • Applications of Systemic Radiation Therapy

Chapter 11 Market Breakdown by Region

Chapter 12 Patent Analysis

  • U.S. Patent Analysis

  • European Patent Analysis

  • Japanese Patent Analysis

Chapter 13 Competitive Landscape

  • Global Company Share Analysis

  • Mergers and Acquisitions

  • Agreements, Collaborations, Product Launches and Partnerships

Chapter 14 Company Profiles

  • Accuray Inc.

  • Advanced Accelerator Applications Sa (Novartis)

  • Alliance Medical Group

  • Bayer Pharma Ag

  • Becton, Dickinson And Co. (Bd)

  • Bracco Diagnostic Inc.

  • Cardinal Health

  • Coqui Radiopharmaceuticals Corp.

  • Curium

  • Eckert & Ziegler Bebig

  • Elekta

  • Fujifilm Holdings Corp.

  • General Electric Co.

  • Iso-Tex Diagnostics Inc.

  • Jubilant Draximage Inc.

  • Lantheus Medical Imaging Inc.

  • National Centre For Nuclear Research Polatom

  • National Institute For Radioelements (Ire)

  • Nordion Inc.

  • Ntp Radioisotopes Soc Ltd.

  • Pharmalucence Inc.

  • Pmb Alcen

  • Siemens Healthcare

  • Vivos Inc.

For more information about this report visit https://www.researchandmarkets.com/r/9t2idz

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/the-worldwide-radiotherapy-radiopharmaceuticals-and-nuclear-medicine-industry-is-expected-to-reach-28-5-billion-by-2026--301409677.html

SOURCE Research and Markets

Recommended Stories

  • Cortexyme Loses 70% Of Its Value On Missed Alzheimer's Test — But There's A Caveat

    Cortexyme said Tuesday it narrowed the pool for its Alzheimer's drug after only certain patients responded. But CRTX stock could dive.

  • Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound

    Bristol Myers Squibb Co on Wednesday said its third-quarter sales rose 10% and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year. Bristol Myers raised the low end of its full-year adjusted profit forecast by 5 cents and now expects to earn $7.40 to $7.55 per share. Bristol Myers had missed analysts' estimates in the first quarter, largely due to a decline in sales of its growth driver, the cancer immunotherapy Opdivo.

  • Sorrento: Covid-19 Tests Could Generate Significant Revenue, Says Analyst

    Shares of Sorrento Therapeutics (SRNE) have been on the backfoot for most of the year, retreating by 63% since the February peaks. Throughout the downturn, however, one Street analyst has been backing the biotech; H.C. Wainwright’s Ram Selvaraju thinks the stock is poised to claw back those gains and some. The analyst reiterated a Buy rating on SRNE, along with a $26 price target. If correct, investors could be lining their pockets with a huge 286% gain. (To watch Selvaraju’s track record, click

  • Jack Ma Tours Netherlands in Farming Technology Quest, SCMP Says

    (Bloomberg) -- Jack Ma, the co-founder of Alibaba Group Holding Ltd., is visiting research institutions in the Netherlands to further his interest in agriculture-related technology, South China Morning Post reported Tuesday.Most Read from BloombergA Deep Dive Into Squid Game's World of InequalityHamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaMeet Six People Fighting Water Scarcity Across the GlobeThe Coming Electric Car Disruption That Nobody’s Talking AboutMa, who is traveling t

  • AbbVie Takes Another Step Toward Its Post-Humira Future

    Skyrizi is an important drug for AbbVie's future that could soon be approved for another indication in the E.U.

  • U.S. demand for oil surges, depleting tanks in Oklahoma

    Crude oil tanks at the Cushing, Oklahoma storage hub are more depleted than they have been in the last three years, and prices of further dated oil contracts suggest they will stay lower for months. U.S. demand for crude among refiners making gasoline and diesel has surged as the economy has recovered from the worst of the pandemic. Demand across the globe means other countries have looked to the United States for crude barrels, also boosting draws out of Cushing.

  • Oil Declines After Industry Report Shows Rising U.S Inventories

    (Bloomberg) -- Oil’s bumper rally cooled after an increase in U.S. crude inventories and as industrial commodities retreated.Most Read from BloombergA Deep Dive Into Squid Game's World of InequalityHamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaMeet Six People Fighting Water Scarcity Across the GlobeThe Coming Electric Car Disruption That Nobody’s Talking AboutGlobal benchmark Brent fell 1.4%, after failing to break through its 2018 high so far this week. The American Petroleum I

  • This Little Company Thinks It Can Beat Long Covid

    The mitochondria of certain SARS-CoV-2 patients malfunction, as if their batteries can't hold a charge. A treatment from Axcella Health aims to offer a jump-start.

  • McDonald's Q3 earnings jump as bigger orders, menu deals boost sales

    The Golden arches posted a major beat in its third quarter results.

  • Oil drops more than 1% as U.S. stockpiles sap rally

    LONDON (Reuters) -Oil prices fell on Wednesday after industry data showed crude oil stockpiles rose more than expected and fuel inventories increased unexpectedly last week in the United States, the world's largest oil consumer. Brent oil futures fell $1.01 cents, or 1.2%, to $85.39 a barrel by 1050 GMT after closing at the highest level in seven years on Tuesday. West Texas Intermediate (WTI) futures were down $1.19, or 1.4%, at $83.46 after gaining 1.1% in the previous session.

  • The top sleep tip trending on TikTok and other hacks to sleep well

    Has sleep been evading you? Here are some tips to enjoy a good night's sleep – no medication required.

  • Silver Price Prediction – Prices Drop on Strong Confidence Report

    Home sales rise

  • Coal Piles at 24-Year Low at U.S. Utilities on Demand Surge

    (Bloomberg) -- Coal stockpiles at U.S. power plants plunged to the lowest in at least 24 years as electricity generators burn the fuel faster than miners can dig it out of the ground. Most Read from BloombergA Deep Dive Into Squid Game's World of InequalityHamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaMeet Six People Fighting Water Scarcity Across the GlobeThe Coming Electric Car Disruption That Nobody’s Talking AboutInventories fell to 84.3 million tons in August, according to

  • Was Atea Pharmaceutical's Flop Predictable?

    This month, as Merck (NYSE: MRK) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19, Atea Pharmaceuticals (NASDAQ: AVIR) stock saw a significant drop. Unfortunately, investors are unlikely to see the small-cap biotech replicate Moderna's success as the next COVID-19 underdog success story after news of its negative clinical trial. Let's explore what caused Atea's drop and how biotech investors should examine their future investments.

  • Long COVID ‘affects every single aspect of a person’s daily life and daily functioning,’ including employment: study

    A new study from researchers at Mount Sinai shows just how serious long COVID can be, and how long it can last --- even for patients who weren't hospitalized.

  • 3 Top COVID Stocks -- Are They Tricks or Treats?

    Taylor Carmichael (Novavax): Novavax's COVID-19 vaccine is still not on the market anywhere, which has made the stock a real wild ride for investors. The vaccine specialist started off 2020 so small it almost qualified as a micro-cap, with its stock priced at $4 a share. When COVID-19 hit, however, the stock took off.

  • Top Tech Stocks for November 2021

    The sector includes companies with the largest market capitalizations in the world, such as Apple Inc. (AAPL), Microsoft Corp. (MSFT), and Amazon.com Inc. (AMZN). Tech stocks, represented by the Technology Select Sector SPDR Fund (XLK), have outperformed the broader market over the past year. Here are the top five tech stocks with the best value, fastest growth, and most momentum.

  • Is Exxon Stock A Buy Ahead Of Q3 Earnings As Oil Prices Hit Multi-Year Highs?

    Exxon Mobil is set to report Q3 results as oil prices hit multi-year highs. Is XOM stock a buy ahead of earnings?

  • Is Merck Stock A Buy After Its Covid Pill Offers New Hope In The Pandemic?

    Is Merck stock a buy after its Covid pill, molnupiravir, offers a new hope in the fight against Covid-19? Is MRK stock a buy now?

  • Big Oil Is About to Post Highest Cash Flow in More Than 13 Years

    (Bloomberg) -- The Western world’s biggest oil companies likely just generated more cash than at any time since the Great Recession, and investors are about to find out what they’ll do with it.Most Read from BloombergCities' Answer to Sprawl? Go Wild.Hamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyOne of California’s Wealthiest Counties Could Run Out of Water Next SummerThe Top Money Maker at Deutsche Bank Reaps Bi